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journal.publications.chestneA young woman received a diagnosis of abdominal, sporadic lymphangioleiomyomatosis (LAM)
and multiple abdominal lymphangioleiomyomas and was referred for recurrent chylous ascites
responding only to a fat-free diet. On admission, pulmonary function test (PFT) results showed
a moderate reduction in the transfer factor for carbon monoxide with normal exercise perfor-
mance. The serum vascular endothelial growth factor D (VEGF-D) level was 2,209 pg/mL. DNA
sequences, amplified at loci kg8, D16S3395, D16S3024, D16S521, and D16S291 on chro-
mosome 16p13.3, showed a loss of heterozygosity (LOH) only for kg8. Fat-free total parenteral
nutrition in association with sirolimus (2 mg po daily) was initiated. Serum sirolimus levels were
maintained at concentrations between 5 and 15 ng/mL. After 1 month, reintroduction of a
low-fat oral feeding was achieved without recurrence of ascites. PFT results were stable.
Interestingly, clinical improvement was associated with a reduction in the VEGF-D serum level
(1,558 pg/mL). LOH at the kg8 biomarker in blood LAM cells was no longer detected.
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A 39-year-old woman received a diagnosis
of multiple retroperitoneal, retrorenal, and
retropancreatic masses seen on an abdominal
CT scan performed for a subfascial abscess
following caesarean section. A biopsy
specimen from the biggest mass was
consistent with a lymphangioleiomyoma.
A subsequent chest CT scan showed diffuse
thin-walled lung cysts suggestive of
lymphangioleiomyomatosis (LAM).
Six months later, ascites was detected by
abdominal ultrasound and 6 L of chylousphangioleiomyomatosis; LOH = loss of
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t.orgfluid was drained. The patient was given
fat-free, total parenteral nutrition (TPN)
with complete resolution of the abdominal
effusion, but a relapse occurred in the
attempt to shift from parenteral to enteral
nutrition. The patient was referred to our
center.
On admission, the patient was in good
health, with an indwelling drainage catheter
in place.
Pulmonary function test results showed a
moderate reduction in the transfer factor for
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predicted value; FVC: 2.21 L, 72% of the predicted value;
TLC: 3.98 L, 86% of the predicted value; transfer factor
for carbon monoxide: 12.7 mL/min/mm Hg, 52% of
the predicted value) and a normal 6-minute walking
distance, without clinically significant desaturation.
Blood test results were within normal limits except
for a high serum level of vascular endothelial growth
factor D (VEGF-D) (2,209 pg/mL). VEGF-D is a
lymphangiogenic growth factor, which plays a key
role in tumor metastasis. It is also a useful biomarker
in LAM, used for diagnosis in patients with cystic
lung disease and no extrapulmonary manifestations.
It directly correlates with disease severity and response
to treatment.1
LAM cells were isolated from the patient’s blood by
fluorescence-activated cell sorting as previously
described.2 DNA sequences were amplified at loci kg8,
D16S3395, D16S3024, D16S521, and D16S291 on
chromosome 16p13.3, near the tuberous sclerosis
complex 2 (TSC2) gene2 (Fig 1A). Quantitative loss96
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Figure 1 – A-D, A 29-year-old woman affected by lymphangioleiomyomatos
phangioleiomyoma appearing as a mass with enhancement and low-density i
cells were amplified at loci kg8, D16S3395, D16S3024, D16S521, and D16S2
heterozygosity (LOH) was detected only for kg8 (A). LOH was no longer dete
complete resolution of abdominal ascites and a reduction in size of the lymp
e30 Selected Reportsof heterozygosity (QLOH) was calculated and evaluated
as described.3 LOH was detected only for kg8.
The initial attempt to feed the patient with a low-fat
enteral diet caused a relapse of abdominal pain, with
large ascites and multiple abdominal masses on CT
scan (Fig 1B). Fat-free TPN in association with sirolimus
(2 mg po daily) was started. After several days we
added a low dose of fat in the parenteral nutrition.
After discharge, the patient continued this parenteral
nutrition with a monthly check of liver function test
results and serum sirolimus levels to maintain a
concentration between 5 and 15 ng/mL. After 1 month,
the reintroduction of low-fat oral feeding was achieved
without recurrence of ascites.
After 3 months, MRI showed that the abdominal masses
were smaller when compared with the previous
abdominal CT scan (Fig 1C), with no signs of ascites.
Pulmonary function test results were stable and the
serum VEGF-D level was 1,558 pg/mL. Interestingly,D
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is presented on CT scan with ascites (*) and a retroperitoneal lym-
ntralesional area (þ) (B). DNA sequences of lymphangioleiomyomatosis
91 on chromosome 16p13.3. Before sirolimus therapy was begun, loss of
ctable after 1 month of treatment (D). This finding was associated with
hangioleiomyoma (C).
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LAM cells in blood having TSC2 LOH at the kg8
biomarker were no longer detected (Fig 1D). The
patient continued the same sirolimus treatment regimen
and was stable at follow-up visits at 6, 12, and 18 months
with a normal diet regimen. Recurrent ascites was not
observed by abdominal ultrasound.Discussion
LAM, a rare multisystem disease affecting primarily
women, is characterized by the dissemination of
abnormal smooth muscle-like LAM cells, leading to
cystic lung destruction, development of thoracic and
abdominal lymphatic masses, and abdominal
angiomyolipomas. LAM may occur sporadically or in
association with tuberous sclerosis complex (TSC).4,5
The metastatic dissemination of LAM cells, bearing
inactivating mutations or LOH of the tumor suppressor
gene TSC1 or TSC2, is hypothesized to be the cause
of the disease.2,6 Sirolimus, approved by the US Food
and Drug Administration for the treatment of LAM,
is an inhibitor of mechanistic target of rapamycin
complex 1 (mTORC1) and an immunosuppressant,
which was shown to decrease the size of
angiomyolipomas in patients with TSC-related and
sporadic LAM.7 The effect of sirolimus on lung
function in LAM was studied in a multicenter,
double-blinded trial (MILES [Multicenter International
Lymphangioleiomyomatosis Efficacy of Sirolimus] trial)
of 46 patients treated with sirolimus and 43 with
placebo. The sirolimus group, when compared with
patients taking placebo, showed significant
improvements in FVC and functional performance
status, with a stabilization of FEV1.
8 The effect of
sirolimus on circulating LAM cells was evaluated in
23 patients with LAM. After 2 years of treatment, on
average, detection of LAM cells was significantly
decreased in blood (from 100% to 25%) and urine
(from 75% to 8%).9
Sirolimus was found to be effective in patients with
thoracic chylous effusions. In fact, Taveira-DaSilva
et al10 described 12 patients with LAM with chylous
abdominal and thoracic effusions and in whom
complete resolution was observed in nine of 11 patients
with pleural effusions and in all eight patients affected
by ascites after 410  111 days of sirolimus therapy.
Before the availability of sirolimus for the treatment of
patients with LAM, the management of chylous ascites
was difficult. Diuretics, paracentesis, and a low-fat diet,
with mainly medium-chain triglycerides, were used tojournal.publications.chestnet.orgreduce the production of chylous effusions. In other
cases, a surgical approach was considered.11
We report the case of a woman with sporadic LAM,
who had mild/moderate respiratory disease, multiple
abdominal lymphangioleiomyomas, and recurrent
chylous ascites. After 3 months of therapy with
sirolimus, complete resolution of the chylous ascites
was observed, with disappearance from the blood of
circulating LAM cells bearing the TSC2 LOH. The
simultaneous restarting of TPN and introduction of
sirolimus may be a potential confounder, as it has
been reported that TPN alone decreases the volume
of lymphangioleiomyomas and alleviates obstruction
in the abdomen. In our case, when the patient was
treated with TPN in another hospital, although a
resolution of chylous ascites was observed, abdominal
masses were not reduced in size, and at the time of
admission to our center, VEFG-D values were high.
Thus, TPN alone was not effective in reducing the
size of the lymphangioleiomyomas.
Although resolution of chylous ascites after treatment
with sirolimus has been described in a previous article,9
as has the effect of treatment on the disappearance of
circulating blood LAM cells,10 this case describes for
the first time, to our knowledge, a direct temporal
relationship between clinical response to sirolimus
and disappearance of blood circulating LAM cells in
a patient with chylous ascites.
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